Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Abuse-resistant controlled-release opioid dosage form

a technology of controlled release and dosage form, which is applied in the direction of drug compositions, heterocyclic compound active ingredients, biocide, etc., can solve the problems of modern society, abuse of opioids, especially heroin, and abuse of opioids, including morphine, codeine, etc., to suppress the euphoric effect of opioids, block the euphoric effect of agonists, and high oral:parenteral potency ratio

Inactive Publication Date: 2008-03-20
PURDUE PHARMA LP
View PDF9 Cites 50 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a type of opioid tablet that is resistant to abuse and has controlled release properties. The tablet contains a combination of an opioid antagonist and an opioid agonist. The antagonist is present in a controlled-release matrix and is released over time, while the agonist is released quickly in a single dose. This combination of antagonist and agonist helps to block the effects of the opioid and reduce the risk of abuse.

Problems solved by technology

Opioid compounds have long been known both for their powerful analgesic properties, and for their strong potential for abuse.
While highly effective at controlling pain, opioids can also be addictive.
Abuse of opioids, particularly heroin, but also including morphine, codeine, oxycodone, hydromorphone, oxymorphone, and others, is a problem in modern society.
These street drugs are of questionable quality.
To do so, the tablets are crushed and often dissolved.
Naloxone is highly effective when taken parenterally, but poorly effective when taken orally because of its metabolism in the liver and, thus, has a high oral:parenteral potency ratio.
Because antagonists such as naloxone are less effective when taken orally, they have not been used to deter oral abuse and have been limited to deterring parenteral or intranasal abuse.
Prior oral opioid dosage formulations contained relatively low doses of opioid and were not generally targets for oral abuse.
Their immediate release formulations release the opioid all at once, but with low amounts of opioid that would not be sufficient for oral abuse without putting several low dosage units together.
The antagonist is present and released in amounts, over time, that attenuate or reduce the side effects of the opioid agonist, yet in amounts insufficient to block the opioid effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] The present invention employs the principle that certain opioid antagonists are ineffective in low oral doses. Therefore, one can administer a low oral dose over a long period of time (controlled release) from a tablet containing a large, orally effective amount of antagonist, without adversely affecting the action of the opioid. However, if the antagonist is administered all at once, it will block the opioid effect and may induce withdrawal in dependent individuals.

[0014] The present invention is intended for use in controlled release compositions. The term, “controlled release” or “CR” when used herein, is intended to refer to tablets intended to release an active pharmaceutical ingredient over an extended period of time, usually over 4 hours, generally 8-12 or up to 24 hours. One method of determining this is to check the intended dosing schedule. Any tablet intended to be taken less frequently than once every four hours should be considered controlled release regardless ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as an immediate release product as a single dose. The controlled release nature of the tablet prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.

Description

[0001] This application is a divisional of U.S. Ser. No. 10 / 143,111 filed on May 10, 2002 and claims benefit of priority to U.S. Provisional Application No. 60 / 290,439 filed on May 11, 2001.FIELD OF THE INVENTION [0002] The present invention relates to controlled-release analgesic pharmaceutical formulations. More specifically, the invention relates to abuse-deterring controlled-release analgesic tablets. BACKGROUND OF THE RELATED ART [0003] Opioid compounds have long been known both for their powerful analgesic properties, and for their strong potential for abuse. While highly effective at controlling pain, opioids can also be addictive. Abuse of opioids, particularly heroin, but also including morphine, codeine, oxycodone, hydromorphone, oxymorphone, and others, is a problem in modern society. Opioid addicts can obtain drugs from a variety of illicit sources. These street drugs are of questionable quality. Therefore, to potential abusers, prescription pharmaceutical opioids can be...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/485A61K9/14A61P25/36A61K9/22A61K9/20A61K31/135A61K31/473A61K45/00A61K47/04A61K47/12A61K47/20A61K47/32A61K47/38A61P25/04
CPCA61K9/2018A61K9/2027A61K9/2054A61K9/20A61K31/485A61K9/0002A61K2300/00A61K31/46A61P25/04A61P25/36A61P43/00A61K9/48A61K9/0053A61K9/4858A61K9/4866A61K9/2013
Inventor CARUSO, FRANKKAO, HUAI-HUNG
Owner PURDUE PHARMA LP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products